Kawasaki disease (KD) is a pediatric acute multisystemic vasculitis complicated by development of coronary artery lesions. The breakthrough theory on KD etiopathogenesis points to pathogens/environmental factors triggered by northeastern wind coming from China. Natural Killer cells and T lymphocytes express the inhibitory/activating Killer Immunoglobulin-like Receptors (KIR) to elicit an immune response against pathogens by binding to human leukocyte antigens (HLA) class I epitopes. We first report on the role of KIR/HLA genetic epistasis in a sample of 100 Italian KD children. We genotyped KIR, HLA-A, HLA-B and HLA-C polymorphisms, and compared KD data with those from 270 Italian healthy donors. The HLA-A*11 ligand for KIR2DS2/2DS4/3DL2 was a KD susceptibility marker by itself (odds ratio (OR) = 3.85, confidence interval (CI) = 1.55-9.53, P = 0.004). Although no epistasis between HLA-A*11 and KIR2DS2/S4 emerged, HLA-A*11 also engages KIR3DL2, a framework gene encoding for a pathogen sensor of CpGoligodeoxynucleotides (CpG-ODN), and KD blood mononuclear cells are actually prone to pathogen CpG-ODN activation in the acute phase. Moreover, carriers of KIR2DS2/HLA-C1 and KIR2DL2/HLA-C1 were more frequent among KD, in keeping with data demonstrating the involvement of these HLA/KIR couples in autoimmune endothelial damage. The highest KD risk factor was observed among carriers of KIR2DL2 and two or more HLA ligands (OR = 10.24, CI = 1.87-56.28; P = 0.007).
INTRODUCTION
Kawasaki disease (KD) is an acute multisystemic febrile vasculitis that affects young children, primarily under 5 years of age. The incidence of KD is at least 11 times higher in Japan and in other East Asian countries than in the Western populations. 1 The few data available about Italian patients show an annual incidence of KD estimated to be 14.7/100.000 children. 2 Classic KD clinical findings are high and persistent fever, bilateral conjunctival injection, cervical lymphadenopathy, erythematous rash, changes in the extremities and changes of lips and oral cavity; however, incomplete and atypical KD forms exist too. 3 The main complication of KD is the occurrence of coronary artery lesions (CALs): aneurisms develop in about a quarter of untreated patients, but timely treatment with intravenous immunoglobulin dramatically reduces the prevalence of aneurisms from 15-25% to 5%. 4, 5 The risk of CALs is higher in non-responders and in case of late treatment, causing acquired heart disease in these patients. 6 Although the aetiopathogenesis of KD is still unknown, the leading hypothesis is that infectious agents cause the disease in a subset of genetically predisposed children through an inflammatory pathway based on the dysregulation of the immune system, leading to cell damage and subsequent vasculitis. 7, 8 The genetic predisposition to develop KD has been already highlighted by both classic polymorphism definition and genome-wide association studies. [9] [10] [11] [12] Human leukocyte antigens (HLA) polymorphisms of class I and II genes have been definitely associated with KD in several genetic studies worldwide, but these analyses never found the same HLA alleles to be associated to the disease. 9, 10 These different results may be due in part to the ethnicity of patients (most of all from Asiatic populations) and partly to the classical analysis of HLA polymorphisms, which considers only alleles encoding for molecules functioning as peptide presenters to the T-cell receptor, ignoring the role of the HLA molecules as ligands for killer immunoglobulin-like receptors (KIR). KIR are a family of genes (19q13.4) encoding for activating and inhibitory transmembrane receptors expressed on the surface of natural killer (NK) cells and subsets of T lymphocytes. KIR recognize polymorphic epitopes of HLA class I membrane ligands to regulate the innate immune response against pathogens and tumor cells. Emerging evidences highpoint that the combination of specific KIR/HLA functional couples can give a broader perspective on the pathogenesis of autoimmune diseases and their genetic susceptibility. 13 The most recent theory of an aetiopathogenetic agent triggering KD claims the mycotoxins as the culprit for the onset of KD with Candida and Aspergillus spores as the main triggers. Carried by the winds coming from northeastern China, the mycotoxins were detected in the air samples at different altitudes by molecular analyses. 14 In agreement with this hypothesis, it has been previously demonstrated that KD is inducible by Candidatoxin intraperitoneal injections in genetically predisposed murine models. 15 Considering that NK cells have an intense antifungal activity and that perturbation in NK cell activation results in an impairment of host response to infections, we decided to verify for the first time if a genetic unbalance in the KIR/HLA receptor/ ligand interplay can contribute to KD susceptibility in a sample of Caucasian patients from Italy. 16 
RESULTS

Killer immunoglobulin-like receptors (KIR) gene content
We compared the frequencies of each KIR gene and pseudogene between our 100 KD children and 270 Italian Caucasian controls (unrelated blood or bone marrow donors (UBMD)). 17 We only found a borderline significant lower frequency of the activating KIR2DS3 gene in KD (29.00% KD vs 38.52% UBMD, P = 0.09). Figure 1 shows the frequencies of all KIR genes in both KD and UBMD.
KIR phenotypic combinations
We analyzed the KIR phenotypes identified by the presence/ absence of the 15 KIR genes and two pseudogenes. As it is not possible to establish the correct order of KIR genes without an informative family study, Table 1 reports only KIR phenotypes, and the order of KIR genes does not follow the physical distribution on chromosome 19 from the centromeric to the telomeric region. We observed 108 different KIR phenotypes carried by KD children and UBMD. In particular, Table 1 lists the first 20 KIR phenotypes present with a frequency ⩾ 1% in KD. Only the frequencies of two KIR phenotypes significantly differed between KD and UBMD: phenotype number 2 was more frequent in KD (P = 0.015), whereas phenotype number 19 was less frequent among KD (P = 0.052).
Human leukocyte antigen (HLA) alleles encoding ligands for KIR We analyzed the frequency of HLA-A, HLA-B and HLA-C alleles encoding molecules functioning as KIR ligands in KD and UBMD. All the HLA-C alleles encode for KIR ligands, but they are subdivided in HLA-C1 and HLA-C2 clusters by the sequence motif or epitope present in the α1 helix at amino-acid residues 77-80. The HLA-C1 subset (binding to KIR2DS2 and KIR2DL2/3) comprises the alleles carrying Asparagine at position 80. The C2 group (binding to KIR2DS1 and KIR2DL1/2/3) comprises the alleles carrying lysine at position 80. Although KIR2DL2 and KIR2DL3 are alleles of the same locus and bind the same C1, C2 and HLA-B epitopes, they show different avidity for HLA ligands: KIR2DL2 has a greater binding affinity for all ligands than KIR2DL3. This difference of binding strength can affect the capability of NK cells to mount the immune response. HLA-C*02:02 and HLA-C*05:01 alleles bind the KIR2DL2/L3 with lower affinity than HLA-C1. 18 Contrariwise, only the HLA-B alleles encoding molecules carrying the Bw4 epitope (spanning residues 77-83 in the α1 domain) express ligands for KIR, thus the HLA-B Bw4 molecules bind to KIR3DL1 and KIR3DS1, and the HLA-B Bw6 molecules are not KIR ligands. The Bw4 epitope is also shared by the HLA-A*23, HLA-A*24 and HLA-A*32 molecules that bind to KIR3DL1. Besides, the HLA-A*03 and HLA-A*11 molecules bind to the KIR3DL2 receptor, and HLA-A*11 also binds to KIR2DS2 and KIR2DS4. 19, 20 Figure 2 shows the frequencies of the HLA alleles encoding ligands for KIR in both KD and UBMD. We only found a significant increase of HLA-A*11 allele in KD children compared to UBMD (14.00% KD vs 6.30% UBMD; P = 0.001).
Epistasis between KIR and HLA genes
We considered the presence of each KIR gene with the HLA allele encoding for the corresponding ligand as genetic blocks linked by virtue of the shared function in modulating the NK and T-cell activity. Table 2 shows all KIR/HLA couples and the function exerted on NK activity by their interaction (inhibitory or activating). We analyzed all these combinations to verify the influence of each KIR-HLA combination in KD susceptibility. 21 We found an unbalance between the concomitant presence of the KIR2D genes and the HLA-C1 alleles encoding for the corresponding ligands. Carrying independently the activating KIR2DS2 gene or one or two HLA-C1 alleles seems to protect against KD, but only KIR2DS2 shows statistical significance (odds ratio (OR) = 0.33, confidence interval (CI) = 0.12-0.95, P = 0.039). When the KIR2DS2 gene is present in conjunction with one or two HLA-C1 alleles (HLA-C1 or HLA-C1/HLA-C1), these combinations are a risk factor for KD development, in particular the second one (KIR2DS2 and HLA-C1/HLA-C1: OR = 3.85, CI = 0.96-15.50; P = 0.05) (Figure 3 top). Likewise, carrying independently the inhibitory KIR2DL2 gene or one or two HLA-C1 alleles seems to protect against KD, but only KIR2DL2 shows statistical significance (OR = 0.34, CI = 0.12-0.98, P = 0.045). When the KIR2DL2 gene is present together with two HLA-C1 alleles, this combination is a risk factor for KD development (KIR2DL2 and HLA-C1/HLA-C1: OR = 4.64, CI = 0.12-0.98; P = 0.032) ( Figure 3 bottom). Moreover, considering all the HLA ligands for KIR2DL2 (Table 2) , we found the highest risk factor for KD development among carriers of KIR2DL2 and two or more HLA is the gene encoding the corresponding functional surface receptor, whereas KIR2DS4del is the gene carrying a deletion that does not allow the expression of the surface receptor. In bold the statistically significant differences are highlighted.
ligands (KIR2DL2 and HLA/HLA ligands for KIR2DL2: OR = 10.24, CI = 1.87-56.28; P = 0.007) ( Figure 4 ).
Finally, we examined the HLA-A*11 allele coupled first with the KIR2DS2 gene and then with the KIR2DS4 gene encoding the corresponding functional surface receptor. 19, 20 In the analysis between HLA-A*11 and KIR2DS2, we found that carrying one HLA-A*11 allele ('KIR2DS2 absence, HLA-A*11 presence') was a risk factor to develop KD by itself (OR = 3.85, CI = 1.55-9.53, P = 0.004), and carrying of at least one HLA-A*11 allele was a threefold risk to develop KD (OR = 3.75, CI = 1.56-9.01, P = 0.003) ( Figure 5 ). Also in the analysis between HLA-A*11 and KIR2DS4, we found that carrying one HLA-A*11 allele ('KIR2DS4 absence, HLA-A*11 presence') was a risk factor to develop KD by itself (OR = 2.56, CI = 1.19-5.51, P = 0.016), and carrying at least one HLA-A*11 allele was a twofold risk to develop KD (OR = 2.42, CI = 1.13-5.18, P = 0.022) ( Figure 5 ). However, the coupling HLA-A*11 and KIR2DS2 or HLA-A*11 and KIR2DS4 was not a risk factor to develop KD ( Figure 5 ). We could not verify the epistatic effect between the HLA-A*11 allele and its KIR3DL2 receptor by the same regression analysis, because KIR3DL2 is a framework gene present in all individuals.
DISCUSSION
High levels of chemokines and proinflammatory cytokines are present in KD patients during the acute phase, but the mechanisms triggering this humoral cascade are still unidentified. Analyses on the cellular milieu of the immune system of KD patients demonstrated that peripheral blood mononuclear cells show a particular activation status, including NK cells and T and B-lymphocytes, therefore a crosstalk among these immune cells may have a pivotal role in KD pathogenesis. [22] [23] [24] As NK cells and subsets of T lymphocytes regulate the adaptive and innate immune responses through the interaction between KIR and HLA class I molecules, we verify for the first time the possible effect of genetic epistasis between KIR and HLA in a sample of 100 Caucasian KD children. First, we analyzed the KIR gene content comparing the frequencies of 15 KIR genes and 2 pseudogenes between KD and 270 Italian UBMD, and we did not find differences (Figure 1 ). Only KIR2DS3 gene, previously reported to be under-represented in patients affected by microscopic polyangiitis, 25 was less frequent among KD, although with borderline statistical significance. Therefore, we considered the different KIR phenotypes, which comprise all the 15 activating/inhibitory genes and two pseudogenes. We found that among KD the phenotype number 2, showing seven inhibitory KIR and only the activating KIR2DS2, was overrepresented ( Table 1) . On the contrary, the phenotype number 19 showing eight inhibitory KIR and the activating KIR2DS2 and KIR2DS3, was under-represented among KD (Table 1 ). These two phenotypes differ for two genes in the centromeric KIR region: the activating KIR2DS3 and the inhibitory KIR2DL5B. Unfortunately, the HLA ligands for both KIR2DS3 and KIR2DL5 are still unidentified. On the other hand, the most frequent KIR phenotype includes only one activating receptor, KIR2DS2, which binds to the HLA-A*11 ligand and displays a weak binding to HLA-C1. 19 Then, we compared the frequencies of the HLA-A, HLA-B and HLA-C alleles encoding ligands for KIR between KD and UBMD. We only found a statistically significant increase of the HLA-A*11 allele (encoding the ligands for KIR2DS2, KIR2DS4 and KIR3DL2) in KD ( Figure 2 ). Furthermore, we verified the presence of one or two HLA alleles coupled with the corresponding KIR gene, and we observed an opposite effect between HLA-C1 alleles and KIR genes. Considering the KIR2DS2/HLA-C1 couple, carrying the KIR2DS2 gene seems to protect against KD, but when the KIR2DS2 gene is present with two HLA-C1 alleles, this combination is a threefold risk factor for KD development (Figure 3 top: KIR2DS2 and HLA-C1/HLA-C1). Emerging evidences correlate the presence of KIR2DS2 with the pathogenesis of vascular damage in several autoimmune conditions also involving inflammation. Studying rheumatoid arthritis patients suffering from vasculitis, Yen et al. 26 found that KIR2DS2 and its HLA-C1 ligands independently contributed to the endothelial damage by regulating a subset of T-cells showing a high expression of KIR2DS2. In agreement with these data, Namekawa et al. 27 found that CD4+CD28null T-cells expressing KIR2DS2 are expanded and cause endothelial damage in rheumatoid arthritis patients. Maybe, similar pathways of vascular damage triggered by KIR2DS2/HLA-C1 could be responsible for KD vasculitis too. Moreover, both KIR2DS2 and KIR2DL2 were more frequent among rheumatoid arthritis patients with vasculitis than in patients without this complication. 28 As to the epistasis between KIR2DL2 and HLA-C1, we observed that carrying two HLA-C1 alleles seems to protect against KD, but when the two HLA-C1 alleles are present with the KIR2DL2 gene, this combination is a threefold risk factor for KD development (Figure 3 bottom: KIR2DL2 and HLA-C1/HLA-C1). Finally, when considering KIR2DL2 with all the HLA possible ligands for this receptors, we observed the highest risk factor for KD in carriers of KIR2DL2 and two or more HLA ligands (Figure 4 : KIR2DL2 and HLA/HLA ligands for KIR2DL2).
The analysis on the epistatic effect between KIR and HLA showed another remarkable result: the HLA-A*11 allele is a new marker of KD susceptibility. The analysis including KIR2DL2 and HLA-A*11 indicated that carriers of at least one HLA-A*11 allele had a threefold risk factor for KD, and the analysis including KIR2DS4 and HLA-A*11 showed that carriers of at least one HLA-A*11 allele had a twofold risk factor for KD ( Figure 4) . However, the risk disappeared considering the HLA-A*11 allele coupled with KIR2DS2 or functional KIR2DS4 genes. These results are understandable if we take into account that the HLA-A*11 allele also encodes a ligand for KIR3DL2, a framework gene present in all individuals. KIR3DL2 has a special domain, which can bind CpG-oligodeoxynucleotides (CpG-ODN) derived from pathogens, co-internalize them into the early endosomal compartment and load them onto toll-like receptor 9. 29 Recent data on the activation status of PBMC in KD patients showed that B-lymphocytes in acute phase of KD are more prone to CpG-ODN activation. 24 As we know that the presence of the HLA ligand increases the expression of its corresponding KIR on the surface of NK cells, 30 the higher sensitivity to CpG-ODN in KD patients may be due, even in part, to the overexpression of KIR3DL2 stimulated by the corresponding ligand encoded by the HLA-A*11 allele. Noteworthy, the HLA-A*11 allele shows a lower distribution in European populations than in Asiatic ethnicities where KD is concomitantly more prevalent.
In our setting, we hypothesize a genetic predisposition to KD involving two phases: KD seems to start as an infectious disease supported by the presence of the HLA-A*11 allele encoding the KIR3DL2 ligand, but evolves as an autoimmune disease triggered by the KIR2DS2/L2 genes coupled with the corresponding HLA-C1 alleles.
PATIENTS AND METHODS
Authors followed the STREGA Statement to write this section. 31 
Patients and controls
Following the American Heart Association guidelines, 3 instruments, Medical Solutions USA, Malvern, USA). Coronaries were classified as normal or dilated on the basis of the Japanese Ministry of Health and Welfare criteria or the Z-scores calculated by the equations of the Children's Hospital Boston, which define coronary artery ectasia if Zscore is between 2 and 3 and coronary artery aneurism if 43. 32, 33 The follow-up period was at least 6 months (from disease onset) for KD children who either never presented CALs (46%) or they had transitory ectasia normalizing within the first 6-8 weeks (19%). Other patients underwent a follow-up of 2 years: only seven children had permanent CALs. All patients, except two who were diagnosed as having KD after the acute phase, received intravenous immunoglobulins at a dosage of 2 g kg − 1 for one day. We considered as controls 270 Italian Caucasian unrelated bone marrow donors (UBMD) belonging to 22 different HLA laboratories along Italy. 17 Patients and controls were matched for ethnicity. The Ethic Committees approved the study protocol, and all patient's parents signed a written informed consent.
Genotyping of KIRs
The KIR gene cluster (19q13.4) consists of 15 genes (2DL1, 2DL2, 2DL3, 2DL4, 2DL5A, 2DL5B, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DS1, 3DL2 and 3DL3) and two pseudogenes (2DP1 and 3DP1), and exhibits polymorphism in the number and the type of activating or inhibitory KIR. We verify the KIR gene content in 100 KD children in terms of presence/absence of the 15 KIR genes and two pseudogenes by PCR with sequence-specific primers, following the manufacturer's instruction (Genovision, Olerup Saltsjöbaden, Sweden). 17 
Molecular typing for HLA polymorphisms
We defined HLA-A and HLA-B polymorphisms at low-resolution level and HLA-C polymorphisms at high-resolution level by PCR with sequencespecific primers (INNO-TRAIN Diagnostik Gmbh, Kronberg, Germany) and/or by the reverse PCR sequence-specific oligonucleotide hybridization method (revPCR-SSO) (Innogenetics, Murex Biotech Limited, Ghent, Belgium), following the manufacturer's instruction. 34, 35 Ambiguous typing results were resolved by direct sequencing. When only one allele was detected, the subject was considered homozygote.
All the 22 laboratories that provided controls have received the European Federation for Immunogenetics accreditation following the European Federation for Immunogenetics accreditation program. The 22 laboratories carried out all the molecular analyses by the same procedures and in agreement with the European Federation for Immunogenetics standards for quality controls.
Statistical analysis
Differences in KIR gene or phenotype frequencies and in HLA allele frequencies between groups were compared with Χ 2 statistics or Fisher's exact test (as appropriate). A logistic multivariate regression analysis with interaction term was used to analyze the effect of the genetic epistasis among KIR and the corresponding HLA ligands. Results are expressed as OR with 95% CI. Significance was set at P ⩽ 0.05 and all tests were two-sided. Data analysis was performed with the STATA statistical package (Ver.13.1, 2012, Stata Corporation, College Station, TX, USA).
